research use only
Cat.No.S6561
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other Sigma Receptor Inhibitors | BD-1047 dihydrobromide PRE-084 hydrochloride Ditolylguanidine S1RA Siramesine HCl Anavex 2-73 HCl Carbetapentane WQ 1 Siramesine Cutamesine Dihydrochloride |
|
In vitro |
DMSO
: 84 mg/mL
(199.86 mM)
Ethanol : 5 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 420.29 | Formula | C19H21IN2O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 155798-08-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CN(CCC1NC(=O)C2=CC=C(C=C2)I)CC3=CC=CC=C3 | ||
| Targets/IC50/Ki |
σ1 receptor
1.7 nM(Ki)
σ2 receptor
25.2 nM(Ki)
|
|---|---|
| In vitro |
4-IBP decreases the migration levels of various types of cancer cells, including C32 melanoma, U373-MG glioblastoma, A549 NSCLC, and PC3 prostate cancer cells. This compound modifies the sensitivity of U373-MG cells in vitro to proapoptotic lomustin and proautophagic temozolomide, and markedly decreases the expression of two proteins involved in drug resistance: glucosylceramide synthase and Rho guanine nucleotide dissociation inhibitor. |
| In vivo |
In vivo, 4-IBP increases the antitumor effects of temozolomide and irinotecan in immunodeficient mice that are orthotopically grafted with invasive cancer cells. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.